

## Anti-PSGL1/CD162 Antibody (Neihulizumab)

### Introduction

Neihulizumab (ALTB-168) is an immune checkpoint agonist antibody that binds to human CD162 (PSGL-1). Neihulizumab is being investigated in steroid-refractory acute graft-versus-host disease (SR-aGVHD), psoriasis, psoriatic arthritis, and ulcerative colitis.

### Product parameters

Alternative Names	ALTB-168, AbGn-168H
Target Accession	Q14242
Target	PSGL1 / CD162
CAS number	2158362-38-8
Molecular Weight	145.72 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human PSGL1 / CD162 HEK293T Cell Line were stained with Anti-PSGL1/CD162 Antibody (Neihulizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

